ClinicalTrials.gg
TerminatedNCT06005428CPVTUpdated May 27, 2026

Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

A Phase 2 interventional study of CRD-4730 and Placebo in CPVT1, Heart Defects, Congenital and Heart Diseases, sponsored by Cardurion Pharmaceuticals, Inc.. Terminated at 11 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Cardurion Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
The early termination of the clinical trial is due to an internal administrative and business decision, the study is not being terminated for safety reasons.

From the registry’s dates

  • Primary completion was May 2025, 1 year 5 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in May 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies in Heart Defects, Congenital with a site in Canada — 16 open to participants now, 22 under way, 2 of them phase 3. Heart Defects, Congenital · Canada.

Enrollment
65th of 69
7 · median 63
Started
2023
with 3 others
Phase 2
7 of 90
none open now
Registered
80th of 90
by date

Among the 90 studies in Heart Defects, Congenital with a site in Canada, this one is the 65th largest by enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2023, is one of 7 in phase 2, and was the 80th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

16 of the 90 studies in Heart Defects, Congenital with a site in Canada are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Heart Defects, Congenital with a site in Canada, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 2 cohorts in which participants with CPVT will participate in a 3-period, randomized 2-sequence study. Each participant will receive 2 different doses of CRD-4730 and 1 dose of matching placebo, with each study drug administered as a single dose.

03

Conditions studied

  • CPVT1
  • Heart Defects, Congenital
  • Heart Diseases
  • Ventricular Tachycardia

Keywords

  • CaMKII
  • Catecholaminergic polymorphic VT
  • Ventricular Tachycardia
  • CRD-4730
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or Females ≥18 years of age, at screening.
  2. Confirmed CPVT diagnosis, based on genetic screening for a known RyR2 mutation and a clinical phenotype consistent with CPVT at screening.
  3. The participant can perform an EST during which frequent premature ventricular contraction (PVCs) (≥10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score ≥2) are identified by the investigator.
  4. Stable doses of any anti-arrhythmic medication, except amiodarone, for 4 weeks prior to screening.
  5. Adhere to all criteria.

Exclusion criteria

Exclusion Criteria:

  1. structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease.
  2. History of a myocardial infarction, cerebrovascular accident, or within 3 months of screening.
  3. History of within the past 5 years at screening (except successfully treated basal cell carcinoma or non- squamous cell carcinoma of the skin or cervical carcinoma in situ).
  4. Female participant that is pregnant or lactating/ breastfeeding, or has plans to do so during the study or within 3 months following last dose of study drug.
  5. Use of amiodarone with 3 months prior to screening. NOTE: other protocol defined Inclusion/ Exclusion criteria may apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Dose 1

    CRD-4730 Dose 1 capsule

    Drug: CRD-4730

  • Experimental
    Dose 2

    CRD-4730 Dose 2 capsule

    Drug: CRD-4730

  • Placebo comparator
    Dose 3

    Placebo capsule to match CRD-4730

    Drug: Placebo

Interventions

  • Oral CRD-4730 in capsule form

  • DrugPlacebo

    Placebo to match CRD-4730 in capsule form

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Events (TEAEs)

    The number of participants with TEAEs including drug-related AEs, serious AEs (SAEs), and AEs leading to study drug discontinuation will be assessed.

    Time frame: Baseline to Day 22

  2. Changes in Laboratory Assessments

    The number of participants who have normal/ abnormal values at Baseline compared to normal/ abnormal values post-Baseline will be assessed for hematology, serum chemistry and urinalysis.

    Time frame: Baseline to Day 15

  3. Changes in Vital Signs Measurement: Systolic and Diastolic blood pressure

    Percent change from Baseline to post Baseline will be assessed for systolic and diastolic blood pressure

    Time frame: Baseline to Day 15

  4. Changes in Vital Signs Measurement: Pulse Rate

    Percent change from Baseline to post Baseline will be assessed for pulse rate

    Time frame: Baseline to Day 15

  5. Changes in Vital Signs Measurement: Respiratory Rate

    Percent change from Baseline to post Baseline will be assessed for respiratory rate

    Time frame: Baseline to Day 15

  6. Changes in Vital Signs Measurement: Body Temperature

    Percent change from Baseline to post Baseline will be assessed for body temperature

    Time frame: Baseline to Day 15

  7. Changes in Physical Exam

    General physical exams will be carried out to detect any abnormalities in the cardiovascular, respiratory and other body systems

    Time frame: Baseline to Day 22

  8. Changes in Electrocardiogram (ECG) Measurements

    Number of participants who have normal/abnormal ECG measurements at Baseline will be compared to normal/abnormal ECG measurement post Baseline

    Time frame: Baseline to Day 22

Secondary outcomes

  1. Change in Ventricular Arrhythmia (VA) score during Exercise Stress Test (EST)

    The VA score is a physician administered score on a scale of 0-5 with higher numbers being worse.

    Time frame: Baseline to Day 1

  2. Change in Ventricular Arrhythmia (VA) score during Exercise Stress Test (EST)

    The VA score is a physician administered score on a scale of 0-5 with higher numbers being worse.

    Time frame: Baseline to Day 8

  3. Change in Ventricular Arrhythmia (VA) score during Exercise Stress Test (EST)

    The VA score is a physician administered score on a scale of 0-5 with higher numbers being worse.

    Time frame: Baseline to Day 15

  4. Assessment of PK effect

    Plasma concentrations of CRD-4730 over time for each treatment period

    Time frame: Baseline through Day 15

07

Study locations

11 sites
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Cleveland Clinic Children's Hospital
    Cleveland, Ohio 44195, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Stollery Children's Hospital University of Alberta
    Edmonton, Alberta T6G 2R7, Canada
  • University of British Columbia (UBC) Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • British Columbia Children's Hospital
    Vancouver, British Columbia V6H 3N1, Canada
  • University of Western Ontario
    London, Ontario N6A 5A5, Canada
  • Hôptal Nord Laennec
    Nantes, Loire-Atlantique 44805, France
  • Hôpital Louis Pradel
    Bron, 69677, France
  • Groupe Hospitalier Bichat Claude Bernard
    Paris, 75018, France
  • IRCCS Pavia Istituti Clinici Scientifici Maugeri Spa Società Benefit
    Pavia, Lombardy 27100, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in May 2025, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2023
First posted
Aug 22, 2023
StartActual
Nov 7, 2023
Primary completionActual
May 31, 2025
CompletionActual
May 31, 2025
Results delay requested
May 14, 2026
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06005428
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 22, 2023
Start date
Nov 7, 2023
Primary completion
May 31, 2025
Completion
May 31, 2025
Last update
May 27, 2026

Study contacts

Jason Homsy, M.D., Ph.D.
study director · Executive Medical Director

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CRD-4730

Start the discussion